The Hep-Net–International Delta Hepatitis Intervention Trial (HIDIT-1) [142] treated 90 chronic hepatitis D (CHD) patients with PEG IFN-α 2a for 48 weeks, with or without Adefovir. This evidence concerns the gene IFNA1 and coronary artery disorder.